Immune self-reactivity triggered by drug-modified HLA-peptide repertoire

Nature

Volumn 486, Issue 7404, 2012, Pages 554-558

  Illing, Patricia T ^a,b   Vivian, Julian P ^c   Dudek, Nadine L ^b   Kostenko, Lyudmila ^a   Chen, Zhenjun ^a   Bharadwaj, Mandvi ^a   Miles, John J ^d,e   Kjer Nielsen, Lars ^a   Gras, Stephanie ^c   Williamson, Nicholas A ^b   Burrows, Scott R ^d   Purcell, Anthony W ^b   Rossjohn, Jamie ^c,e   McCluskey, James ^a,f  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^e CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^f AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALLOPURINOL; CARBAMAZEPINE; HLA B ANTIGEN; T LYMPHOCYTE RECEPTOR;

ALLELE; DRUG; IMMUNE SYSTEM; PEPTIDE; POLYMERIZATION;

AMINO ACID SEQUENCE; ANTIGEN BINDING; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CD8+ T LYMPHOCYTE; COMPLEX FORMATION; COVALENT BOND; CRYSTAL STRUCTURE; DRUG HYPERSENSITIVITY; DRUG PROTEIN BINDING; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HYDROGEN BOND; IMMUNE RESPONSE; IMMUNOREACTIVITY; LEUKEMIA CELL LINE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN STRUCTURE; STEREOCHEMISTRY; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE ACTIVATION; TOXIC EPIDERMAL NECROLYSIS;

ANTIGEN PRESENTATION; AUTOIMMUNITY; BINDING SITES; BLOOD DONORS; CARBAMAZEPINE; CD8-POSITIVE T-LYMPHOCYTES; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; HLA-B ANTIGENS; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; SYNDROME; T-LYMPHOCYTES;

EID: 84862979660     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature11147     Document Type: Article

References (27)

1. McCluskey, J.& Peh, C. A. The human leucocyte antigens and clinicalmedicine: an overview. Rev. Immunogenet. 1, 3-20 (1999).
2. Parham, P. & Ohta, T. Population biology of antigen presentation by MHC class I molecules. Science 272, 67-74 (1996).
3. Bharadwaj,M. et al.Drughypersensitivityandhumanleukocyteantigensof themajor histocompatibility complex.Annu. Rev. Pharmacol. Toxicol. 52, 401-431 (2012).
4. Chung, W. H. et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428, 486 (2004).
5. Daly, A. K. et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nature Genet. 41, 816-819 (2009).
6. Mallal, S. et al. Association between presence of HLA-B*5701, HLA-DR7, and HLADQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359, 727-732 (2002).
7. Hetherington, S. et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121-1122 (2002).
8. Chessman, D. et al. Human leukocyte antigen class I-restricted activation of CD81 T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 28, 822-832 (2008).
9. Purcell, A. W. et al. Quantitative and qualitative influences of tapasin on the class I peptide repertoire. J. Immunol. 166, 1016-1027 (2001).
10. Barber, L. D. et al. Polymorphismin the a1 helix of the HLA-B heavy chain can have an overriding influence on peptide-binding specificity. J. Immunol. 158, 1660-1669 (1997).
11. Macdonald, W. A. et al. T cell allorecognition via molecular mimicry. Immunity 31, 897-908 (2009).
12. Archbold, J. K., Macdonald, W. A., Burrows, S. R., Rossjohn, J. & McCluskey, J. T-cell allorecognition: a case of mistaken identity or déjà vu? Trends Immunol. 29, 220-226 (2008).
13. Turner, S. J., Doherty, P. C., McCluskey, J. & Rossjohn, J. Structural determinants of T-cell receptor bias in immunity. Nature Rev. Immunol. 6, 883-894 (2006).
14. Ko, T. M. et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J. Allergy Clin. Immunol. 128, 1266-1276 (2011).
15. Burrows, S. R., Rossjohn, J. & McCluskey, J. Have we cut ourselves too short in mapping CTL epitopes? Trends Immunol. 27, 11-16 (2006).
16. Hughes, A. R. et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 5, 203-211 (2004).
17. Mallal, S. et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568-579 (2008).
18. Martin, A. M. et al. Predisposition to abacavir hypersensitivity conferred by HLAB* 5701 and a haplotypic Hsp70-Hom variant. Proc. Natl Acad. Sci. USA 101, 4180-4185 (2004).
19. Hung,S. I. et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA 102, 4134-4139 (2005).
20. Brodsky, F. M., Bodmer, W. F. & Parham, P. Characterization of a monoclonal antib2-microglobulin antibody and its use in the genetic and biochemical analysis of major histocompatibility antigens. Eur. J. Immunol. 9, 536-545 (1979).
21. Macdonald, W. et al. Identification of a dominant self-ligand bound to three HLA B44 alleles and the preliminary crystallographic analysis of recombinant forms of each complex. FEBS Lett. 527, 27-32 (2002).
22. Zemmour, J., Little, A. M., Schendel, D. J. & Parham, P. The HLA-A,B 'negative' mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon. J. Immunol. 148, 1941-1948 (1992).
23. Storkus, W. J., Howell, D. N., Salter, R. D., Dawson, J. R. & Cresswell, P. NK susceptibility varies inversely with target cell class I HLA antigen expression. J. Immunol. 138, 1657-1659 (1987).
24. Schuttelkopf, A. W. & van Aalten, D. M. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr. 60, 1355-1363 (2004).
25. Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455-461 (2010).
26. Roder, G. et al. Crystal structures of two peptide-HLA-B*1501 complexes; structural characterization of the HLA-B62 supertype. Acta Crystallogr. D Biol. Crystallogr. 62, 1300-1310 (2006).
27. Szymczak, A. L. et al. Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nature Biotechnol. 22, 589-594 (2004).